Appendix[removed]: Protocol and Protocol Amendments (MA[removed])

First Page		Document Content
Design of experiments Pharmacology Drug safety Institutional review board Clinical trial Lip enhancement Restylane Investigational New Drug Medicis Pharmaceutical Medicine Clinical research Pharmaceutical industry		Appendix[removed]: Protocol and Protocol Amendments (MA[removed]) Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 510,92 KB Share Document on Facebook

	1.5% Contingent Convertible Senior Notes due[removed]the “2033 Notes) Issued by Medicis Pharmaceutical Corporation (“Medicis”) On December 11, 2012, Valeant Pharmaceuticals International, Inc. completed its acquisiti DocID: BVvB - View Document
	1.375% Convertible Senior Notes due[removed]the “2017 Notes”) Issued by Medicis Pharmaceutical Corporation (“Medicis”) On December 11, 2012, Valeant Pharmaceuticals International, Inc. completed its acquisition of DocID: BuID - View Document
	2.5% Contingent Convertible Senior Notes due[removed]the “2032 Notes) Issued by Medicis Pharmaceutical Corporation (“Medicis”) On December 11, 2012, Valeant Pharmaceuticals International, Inc. completed its acquisiti DocID: Bo2s - View Document
	Final Ammonul DHP Letter Future Lots DocID: kc2c - View Document
	Appendix[removed]: Protocol and Protocol Amendments (MA[removed]) DocID: jjIp - View Document